A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
This study is not yet open for participant recruitment.
Verified July 2013 by CytoDyn, Inc.
Information provided by (Responsible Party):
First received: January 5, 2011
Last updated: July 25, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is not yet open for participant recruitment.|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|